StreetInsider.com News Articles

Form 4 Medpace Holdings, Inc. For: Oct 12 Filed by: BURWIG SUSAN E

Wed, 14 Oct 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20261014/27187254.html

Form 4 Medpace Holdings, Inc. For: Oct 07 Filed by: BURWIG SUSAN E

Fri, 09 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261009/27171683.html

Medpace (MEDP) PT Raised to $700 at Mizuho

Wed, 07 Oct 2026 06:44:47 -0400

Mizuho analyst Ann Hynes raised the price target on Medpace (NASDAQ: MEDP) to $700.00 (from $665.00) while maintaining a Outperform rating.

Medpace (MEDP) PT Raised to $625 at Barclays

Wed, 07 Oct 2026 03:50:47 -0400

Barclays analyst Luke Sergott raised the price target on Medpace (NASDAQ: MEDP) to $625.00 (from $600.00) while maintaining a Equalweight rating.

Form 4 Medpace Holdings, Inc. For: Sep 30 Filed by: McCarthy Cornelius P. III

Fri, 02 Oct 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20261002/27143590.html

Form 4 Medpace Holdings, Inc. For: Sep 30 Filed by: Kraft Robert O.

Fri, 02 Oct 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20261002/27143528.html

Form 4 Medpace Holdings, Inc. For: Sep 30 Filed by: Carley Brian T

Fri, 02 Oct 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20261002/27143489.html

Form 4 Medpace Holdings, Inc. For: Sep 29 Filed by: Troendle August J.

Thu, 01 Oct 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20261001/27137427.html

UBS Resumes Medpace (MEDP) at Neutral

Wed, 30 Sep 2026 05:47:56 -0400

UBS analyst Kevin Caliendo resumes coverage on Medpace (NASDAQ: MEDP) with a Neutral rating and a price target of $673.00.

The analyst comments: “We assume coverage of MEDP at Neutral. We believe market expectations for revenue growth and margins are reasonable and valuation is highest in the CRO peer group limiting the potential for multiple upside. Strong 2Q26 results set the bar higher for bookings and earnings in 2H26, which we believe investors are expecting.

TTM biotech funding is up 87% y/y and is highly correlated to bookings, especially MEDP since the company derives 95% of its revenue from biotechs. Biotech R&D

UBS Resumes Medpace (MEDP) at Neutral

Wed, 30 Sep 2026 05:47:56 -0400

UBS analyst Kevin Caliendo resumes coverage on Medpace (NASDAQ: MEDP) with a Neutral rating and a price target of $673.00.

TTM biotech funding is up 87% y/y and is highly correlated to bookings, especially MEDP since the company derives 95% of its revenue from biotechs. Biotech R&D

Form 4 Medpace Holdings, Inc. For: Sep 25 Filed by: Troendle August J.

Tue, 29 Sep 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260929/27122626.html

Medpace (MEDP) PT Raised to $638 at Baird

Tue, 29 Sep 2026 07:18:04 -0400

Baird analyst Eric Coldwell raised the price target on Medpace (NASDAQ: MEDP) to $638.00 (from $624.00) while maintaining a Neutral rating.

Form SCHEDULE 13D/A Medpace Holdings, Inc. Filed by: Troendle August J.

Mon, 28 Sep 2026 19:15:00 -0400

si-local-file:///var/storage/secattach/20260928/27115815.html

Form 4 Medpace Holdings, Inc. For: Sep 23 Filed by: Troendle August J.

Fri, 25 Sep 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260925/27107677.html

Form 4 Medpace Holdings, Inc. For: Sep 21 Filed by: Troendle August J.

Wed, 23 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260923/27096772.html

Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026

Tue, 22 Sep 2026 16:05:00 -0400

CINCINNATI--(BUSINESS WIRE)-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results.

To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation

Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026

Tue, 22 Sep 2026 16:05:00 -0400

Form 4 Medpace Holdings, Inc. For: Sep 17 Filed by: Troendle August J.

Mon, 21 Sep 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260921/27085598.html

Form 4 Medpace Holdings, Inc. For: Sep 15 Filed by: Troendle August J.

Thu, 17 Sep 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260917/27076426.html

Form 4 Medpace Holdings, Inc. For: Sep 15 Filed by: BURWIG SUSAN E

Thu, 17 Sep 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260917/27076375.html

Jefferies Reiterates Hold Rating on Medpace (MEDP)

Mon, 14 Sep 2026 05:57:32 -0400

Jefferies analyst David Windley reiterated a Hold rating and $560.00 price target on Medpace (NASDAQ: MEDP).

The analyst comments "Our HQ visit in Cincy led to four key takes: (1) demand improving, supported by higher quality opportunities; (2) increasing interim analyses are reducing non-NTM backlog visibility without changing backlog policy; (3) productivity gains reflect lower attrition and a more experienced workforce, higher growth could moderate that; and (4) AI may improve efficiency, but mgt expects much of the economic benefit to accrue to sponsors rather than CROs over time."

For an analyst ratings summary and ratings history on Medpace click here.

Innventure names new board chair, accelerates CEO transition

Mon, 31 Aug 2026 08:00:41 -0400

Innventure, Inc. (NASDAQ: INV) announced several leadership and governance changes, including the appointment of Bruce Brown as independent Chairman of the Board, replacing Michael Otworth. The changes were disclosed in a press release dated Aug. 31, 2026.

Brown had served as Lead Independent Director since November 2025 and was unanimously elected Chairman on Aug. 27, 2026. He currently serves on the board of Magnera Corporation (NYSE: MAGN) and previously served on the boards of Nokia Corporation (NYSE: NOK) and Medpace Holdings (NASDAQ: MEDP).

The company also confirmed that Dr. William Grieco will assume the Chief Executive Officer role and a board seat

Innventure names new board chair, accelerates CEO transition

Mon, 31 Aug 2026 08:00:41 -0400

The company also confirmed that Dr. William Grieco will assume the Chief Executive Officer role and a board seat

Innventure names new board chair, accelerates CEO transition

Mon, 31 Aug 2026 08:00:41 -0400

The company also confirmed that Dr. William Grieco will assume the Chief Executive Officer role and a board seat

Innventure names new board chair, accelerates CEO transition

Mon, 31 Aug 2026 08:00:41 -0400

The company also confirmed that Dr. William Grieco will assume the Chief Executive Officer role and a board seat